Implications of Recent Clinical Trials on Pay-for-Performance
Published in: American journal of health-system pharmacy, v. 66, no. 9, May 2009, p. 864-867
Posted on RAND.org on January 01, 2009
Ideally pay-for-performance in chronic diseases would be based on outcomes that really matter to patients, such as death, morbidity, and disability. Instead, many of the quality metrics used in pay-for-performance address process measures (e.g., the percentage of diabetic patients who receive glycosylated hemoglobin [HbA1c] testing or a lipid profile each year). The few measures that attempt to address clinical outcomes actually measure surrogate markers like HbA1c, low-density-lipoprotein (LDL) cholesterol, and blood pressure.